Why the study?
Do sulfonylureas or glitazones alter the risk of acute myocardial infarction compared to metformin?
Do sulfonylureas or glitazones alter the risk of acute myocardial infarction compared to metformin?
Observational evidence suggests sulfonylureas are associated with a higher risk of acute myocardial infarction compared to metformin.
Sulfonylureas may raise AMI risk versus metformin; leaves open causal effects and pioglitazone comparisons pending randomized trials.
Sulfonylureas increased the risk of AMI by 24% compared with metformin; an imprecise point estimate indicated no difference in risk of AMI when comparing pioglitazone with metformin. The presence of heterogeneity precluded any conclusions on the other comparisons. The quality assessment was valuable in identifying methodological problems in the individual studies and for analysing potential sources of heterogeneity.
No takes yet. Share an insight, caveat, or question.
Pladevall et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: